According to Borui Pharmaceutical's announcement, the cumulative deviation value of the company's stock price increase reached 30% for three consecutive trading days on July 14, July 15, and July 16, 2026, which is an abnormal fluctuation in stock trading. After self-inspection and verification with the controlling shareholders and actual controllers, as of the date of disclosure of the announcement, the company's daily operations were normal, there were no major changes, there was no significant information that should be disclosed but not disclosed, and the company's directors, supervisors, controlling shareholders, and actual controllers did not trade the company's shares during this period.

According to Borui Pharmaceutical's announcement, the cumulative deviation value of the company's stock price increase reached 30% for three consecutive trading days on July 14, July 15, and July 16, 2026, which is an abnormal fluctuation in stock trading. After self-inspection and verification with the controlling shareholders and actual controllers, as of the date of disclosure of the announcement, the company's daily operations were normal, there were no major changes, there was no significant information that should be disclosed but not disclosed, and the company's directors, supervisors, controlling shareholders, and actual controllers did not trade the company's shares during this period.